

Developmental Programming and the Placenta: Focusing in on Glucocorticoids

Caitlin S. Wyrwoll

Abstract Fetal glucocorticoid exposure is a key mechanism involved in adverse programming outcomes in the adult. Impairment of fetal growth has predominantly been attributed to direct effects of glucocorticoids on the fetus, prematurely shifting tissue development from a proliferative to a more functionally mature state. However, fetal growth is dependent on a complex interplay of maternal, placental, and fetal endocrine signals, and glucocorticoid-mediated fetal growth retardation is likely also to relate to disturbances in placental growth and function. Regulation of fetal glucocorticoid exposure is achieved by the placental glucocorticoid barrier, which involves glucocorticoid inactivation within the labyrinth zone of the murine placenta by 11 β -hydroxysteroid dehydrogenase type 2 (11 β -HSD2). Overexposure to glucocorticoids or depletion of 11 β -HSD2 has a dramatic effect on placental development and function, with a reduction in capillary networks and alterations in nutrient transport. This work highlights the finding that adverse programming effects of glucocorticoids are not exclusively due to direct actions on the fetus but are also a consequence of changes in placental development and function.

Developmental Programming

Low birth-weight and other indicators of reduced fetal growth are associated with adult cardio-metabolic and psychiatric disease. This association is the result of “developmental programming,” whereby a stimulus during a sensitive period of early development exerts permanent effects on structure, physiology or metabolism (Cottrell and Seckl 2009). The environmental mechanisms of developmental

C.S. Wyrwoll (✉)

The School of Anatomy, Physiology and Human Biology, The University of Western Australia, Perth, WA 6009, Australia
e-mail: caitlin.wyrwoll@uwa.edu.au

programming identified so far can be simplified into two major groups: fetal stress exposure and maternal nutrition, although changes in glucocorticoids appear to underpin the programming effects of both (Langley-Evans et al. 1996; Gardner et al. 2007; Harris and Seckl 2010). In many animals, including mice and humans, there is an increased exposure of the developing fetus to glucocorticoids late in pregnancy, as they have a crucial role in the structural development and functional maturation of fetal organs. However, glucocorticoid overexposure of the fetus can be detrimental, as glucocorticoids cause a shift from cell proliferation to differentiation. Therefore, exposure to excess glucocorticoids in utero alters fetal organ growth and maturation patterns, which can result in adverse consequences in later life. In humans, the actions of glucocorticoids are exploited for preterm births to advance fetal lung maturation (Roberts and Dalziel 2006), although this may set the stage for adverse effects in later life (Benediktsson et al. 1993; Brown et al. 1996a; Levitt et al. 1996; Lindsay et al. 1996; Dodic et al. 1998, 1999, 2002a, b; Gatford et al. 2000; Langdown and Sugden 2001; Jensen et al. 2002).

The Feto-Placental Glucocorticoid Barrier: 11 β -HSD2

As glucocorticoids are highly lipophilic, they readily diffuse across biological membranes and, therefore, control of intracellular levels of bioactive glucocorticoid is critical. This control arises from the enzyme 11 β -hydroxysteroid dehydrogenase (11 β -HSD), which interconverts the active glucocorticoids cortisol and corticosterone with their biologically inactive forms, cortisone and 11-dehydrocorticosterone (DHC), respectively. There are two distinct forms of 11 β -HSD: 11 β -HSD1, which is a low affinity, NADP(H)-dependent bidirectional enzyme, although in vivo it appears to act predominantly as an 11 β -oxoreductase to enhance glucocorticoid activity; and 11 β -HSD2, which is a high affinity NAD-dependent enzyme that exhibits exclusive 11 β -dehydrogenase activity (conversion of corticosterone to DHC) to reduce glucocorticoid potency. 11 β -HSD2 is highly expressed in aldosterone-selective target tissues such as the distal nephron (Roland et al. 1995), colon (Whorwood et al. 1994), salivary glands (Roland and Funder 1996) and skin (Kenouch et al. 1994), thus serving to confer aldosterone specificity on the mineralocorticoid receptor (MR) to which both corticosterone and aldosterone can bind. Importantly, 11 β -HSD2 does not always colocalize with MR, such as within placental and fetal tissues, and so its function has expanded beyond involvement in electrolyte transport to include regulation of corticosteroid action.

During much of normal pregnancy, circulating levels of glucocorticoids in the fetus are substantially lower than in the mother. This difference arises in part from the high expression of 11 β -HSD2 in both the placenta and fetus, and this 11 β -HSD2 expression serves as a “glucocorticoid barrier,” enabling tight regulation of materno-fetal glucocorticoid transfer. Within the placenta, 11 β -HSD2 is highly expressed at the interface between maternal and fetal circulations, in the syncytiotrophoblast in humans (Brown et al. 1996a,b) and the labyrinthine zone in rodents

(Waddell et al. 1998). In the rodent, 11 β -HSD2 expression within the labyrinthine zone of the placenta falls during late gestation, which may facilitate glucocorticoid passage to the fetus and thus lung maturation (Brown et al. 1996a, b; Burton et al. 1996).

The high expression of 11 β -HSD2 in placenta and fetal tissues and the growth-retarding and maturational effects of glucocorticoids upon the fetus (Meyer 1983) have lead to the proposal that variations in feto-placental 11 β -HSD2 may underlie developmental programming. Thus, placental 11 β -HSD2 activity correlates with birth parameters in rodents and, less consistently, in humans (Benediktsson et al. 1993; Stewart et al. 1995; Murphy et al. 2002), suggesting that normal variation in fetal exposure to maternal glucocorticoids has an impact on fetal growth. Numerous studies have shown that inhibition, deficiency or by-pass (poor substrate steroids such as dexamethasone or betamethasone) of 11 β -HSD2 in gestation in rodents and humans associates with alterations in pregnancy duration, birth weight and programmed outcomes in the offspring (Benediktsson et al. 1993; Burton and Waddell 1994; Mune et al. 1995; Lindsay et al. 1996; Dave-Sharma et al. 1998; Nyirenda et al. 1998; Smith and Waddell 2000; Welberg et al. 2000, 2001; O'Regan et al. 2004; Holmes et al. 2006; Wyrwoll et al. 2006, 2007; Newnham and Jobe 2009). Furthermore, maternal stress in rodents during pregnancy has been associated with decreased expression of placental 11 β -HSD2 (Mairesse et al. 2007; Lucassen et al. 2009; Pankevich et al. 2009). Interestingly, programming models involving maternal low-protein diet show an increase in maternal and fetal glucocorticoid levels (Lesage et al. 2001; Guzmán et al. 2006) in addition to a decrease in placental 11 β -HSD2 activity and/or expression (Langley-Evans et al. 1996; Lesage et al. 2001; Stocker et al. 2004). Moreover, dexamethasone administration during pregnancy decreases food intake (Woods and Weeks 2005). Consequently, there seems to be considerable overlap in mechanisms by which maternal undernutrition and fetal glucocorticoid overexposure elicit developmental programming.

Placental 11 β -HSD2 Is More than Just a Glucocorticoid Barrier

As described above, placental 11 β -HSD2 may underpin aspects of developmental programming by allowing excess glucocorticoid passage from the “high” glucocorticoid maternal circulation to the “low” glucocorticoid fetal environment (Edwards et al. 1993), thus impairing fetal growth by direct effects of glucocorticoids on the fetus. Fetal growth is, however, dependent on a complex array of maternal, placental and fetal endocrine signals, and glucocorticoid-mediated fetal growth retardation must also relate, at least in part, to disturbances in placental growth and function. Indeed, treatment of rats with glucocorticoids such as dexamethasone, which are poor substrates for 11 β -HSD2, restricts placental vascular

development, via inhibition of the endothelial cell-specific mitogen, vascular endothelial growth factor-A (VEGF-A), and peroxisome proliferators-activated receptor gamma (PPAR γ), which regulates VEGF-A expression (Hewitt et al. 2006a,b). Impaired vascular arborization within key areas of the placenta that are involved in nutrient exchange between the maternal and fetal circulations is likely to have effects on placental function. However, glucocorticoid effects on placental function have been discordant. Thus, chronic restraint stress during late gestation in rats reduces placental 11 β -HSD2 expression and expression of GLUT1, with an associated reduction in fetal plasma glucose (Mairesse et al. 2007), whereas late gestation dexamethasone increases placental GLUT1 and 3 expression (Langdown and Sugden 2001), and another synthetic glucocorticoid, triamcinolone, down-regulates placental GLUT1 and 3 protein and mRNA (Hahn et al. 1999). Any physiological relevance of these manipulations is unresolved. Furthermore, while system A amino acid transporter (SNAT) activity and expression are upregulated by cortisol exposure in BeWo cells (Jones et al. 2006), they are unaltered in human placental villous fragments exposed to cortisol (Jansson et al. 2003; Ericsson et al. 2005). Importantly, it is unknown whether the above observations of altered placental function in whole animal experiments are a direct effect of glucocorticoids on the placenta or occur via indirect effects on the dam. Thus, recent work utilizing 11 β -HSD2^{+/-} mice sought to demonstrate a direct effect of increased glucocorticoid exposure on placental function. This model of 11 β -HSD2 heterozygous matings, whereby 11 β -HSD2^{+/+}, ^{+/-} and ^{-/-} fetuses are generated by the same mother, clearly demonstrates a direct effect of increased glucocorticoid exposure on placental development and function.

Absence of Placental 11 β -HSD2 Alters Placental Function and Development

Depletion of 11 β -HSD2 in mice (generated by 11 β -HSD2^{+/-} matings) has been recently shown to compromise not only fetal but also placental growth (Wyrwoll et al. 2009) and to increase placental and fetal exposure to glucocorticoids (Cottrell et al. 2012). In this model, as 11 β -HSD2 is expressed in the labyrinth zone of the placenta (which originates from fetal tissue), the genotype of the fetus is also the genotype of the placenta with regard to 11 β -HSD2. At E15, despite a reduction in placental size, fetal weight is maintained, generating an increase in fetal/placental ratio that is indicative of enhanced placental function (Wyrwoll et al. 2009). Indeed, placental amino acid transport of 11 β -HSD2^{-/-} fetuses was upregulated at E15 alongside increased expression of the amino acid transporters *Slc38a2* and *Slc38a4* (Wyrwoll et al. 2009). Later in pregnancy, at E18, the smaller placenta of the 11 β -HSD2^{-/-} fetus appears unable to maintain normal fetal growth, and fetal weight falls behind control littermates (Wyrwoll et al. 2009). At this time, the transplacental transfer of glucose and plasma glucose levels was reduced in

11 β -HSD2^{-/-} fetuses (Wyrwoll et al. 2009). Glucose is a primary nutrient required for fetal development and is transported across the placenta by facilitated diffusion, primarily via GLUT1 and GLUT3 (Uldry and Thorens 2004). The reduced *Slc2a3* expression we observed in the labyrinth zone of placentas from 11 β -HSD2^{-/-} fetuses most likely accounts for the reduction in the transplacental transfer of glucose.

This altered placental function is further associated with reduced capillary networks (Wyrwoll et al. 2009). Thus, 11 β -HSD2^{-/-} placentas have significantly reduced fetal capillary development within the labyrinth zone, the zone regulating nutrient exchange, accompanied by a decline in VEGF-A and PPAR γ mRNA expression, which are factors known to regulate angiogenesis (Wyrwoll et al. 2009). The decrease in fetal capillary vascularity in the 11 β -HSD2^{-/-} placentas may have implications for blood flow within the placenta and the umbilical cord. Indeed, ultrasound measures of blood flow have revealed decreased blood flow in the 11 β -HSD2^{-/-} placenta towards the end of gestation (Wyrwoll, unpublished data). Furthermore, umbilical vein flow in 11 β -HSD2^{-/-} fetuses does not undergo the normal gestational increase that occurs in wild-type littermates (Wyrwoll, unpublished data).

Ultrasound measures have also revealed altered cardiac function in 11 β -HSD2^{-/-} fetuses. Thus, the normal increase in E/A wave ratio [the E wave represents passive filling of the left ventricle (LV) and the A wave represents LV filling due to contraction of the atria] over gestation as the fetal heart becomes more compliant is not apparent in 11 β -HSD2^{-/-} hearts (Wyrwoll, unpublished data). Furthermore, the resistance index [RI = systole/(systole + diastole); systole being blood flow during maximal contraction of the heart and diastole being maximal relaxation] in the umbilical artery does not undergo the normal gestational decline as blood flow from the fetus to placenta increases (Wyrwoll, unpublished data).

These novel ultrasound data have lead to the proposal that impaired placental hemodynamics in the 11 β -HSD2^{-/-} fetus may have direct implications for fetal cardiac function. As the site of gaseous exchange in the fetus is the placenta, fetal circulation is distinct from the postnatal period. Thus oxygenated blood from the placenta travels through the umbilical vein and enters the fetal circulation either through the ductus venosus (a fetal shunt that bypasses the hepatic circulation such that blood is directly delivered into the inferior vena cava) or, after perfusing the liver, enters the inferior vena cava via the hepatic veins. Once circulated, blood returns to the placenta via the umbilical artery. Therefore, given that both the fetal heart and liver are the immediate organs exposed to blood leaving the placenta, the placenta is uniquely placed to have a direct influence on these particular organs. Indeed, epidemiological studies have revealed associations between placental size and the shape and incidence of cardiovascular disease in later life (Barker et al. 2010).

However, the results discussed above provide only indirect evidence of changes in placental blood flow and vascularity impacting on fetal heart development and function. What is required to provide a conclusive link in this relationship is to produce an amelioration of the compromised fetal capillary development in

11 β -HSD2^{-/-} placentas and to then investigate how this alters placental and fetal hemodynamics. Indeed, restoration of angiogenic balance in mouse models of preeclampsia has striking effects. Thus, administration of pravastatin (one of a class of lipid-lowering compounds, the HMG-CoA reductase inhibitors, that reduce cholesterol biosynthesis) in various mouse models of preeclampsia appears to ameliorate preeclamptic pathology (Ahmed et al. 2010, Kumasawa et al. 2011). The precise mechanisms by which this improvement transpires is unclear but there was marked restoration of vasculogenesis in the preeclamptic placentas which has been variously attributed to stimulation of placental VEGF release (Ahmed et al. 2010) or placental growth factor (Kumasawa et al. 2011). The previous finding that VEGF is decreased in the placentas of 11 β -HSD2^{-/-} fetuses and thus presumably accounts for the observed decline in normal fetal capillary development is notable (Wyrwoll et al. 2009).

Therefore, recent work has sought to establish the effects of pravastatin on placental blood flow and fetal heart function of 11 β -HSD2^{-/-} fetuses. Administration of pravastatin to 11 β -HSD2^{+/-} dams from E6 of gestation onwards had marked effects on placental blood flow and fetal heart measures. Thus, both placental blood flow and the fetal cardiac E/A ratio of 11 β -HSD2^{-/-} fetuses remained comparable to those in wild-type fetuses in the pravastatin-treated pregnancies (Wyrwoll, unpublished data). Strikingly, gene expression of placental VEGF-A is upregulated in the pravastatin-treated pregnancies, which would presumably enhance angiogenesis within the placenta, with consequent ramifications for blood flow (Wyrwoll, unpublished data). Characterization of vascularity within these placentas is currently being undertaken to establish if this is indeed the case.

Optimal Placental Function, Optimal Health in Later Life?

The work conducted over the last few years on placental function and development of 11 β -HSD2^{-/-} fetuses provides a convincing argument that, while maternal glucocorticoids could play a direct role in programming the fetus, placental development and function also play key roles. Thus, the observations of altered placental transport of nutrients may have important ramifications for “setting” fetal metabolism and, thus, adult health in later life. Furthermore, the possibility that placental hemodynamics have the potential to alter fetal cardiac development and function opens up a novel research avenue. Additionally, placental function may shape health outcomes beyond cardio-metabolic disease. Indeed, there is growing recognition that the placenta generates hormones that are critical for neural function prior to the time such hormones are produced by the fetal brain itself, raising the possibility that the placenta may have a significant role in fetal neurodevelopment (Bonnin et al. 2011). Therefore, the placenta is key in influencing fetal development and shaping health outcomes in later life.

Acknowledgments This work was supported by a Wellcome Trust project grant (WT079009; MCH, JLP, JJM, JRS). We acknowledge the support of the BHF Centre of Research Excellence.

References

- Ahmed A, Singh J, Ahmed A, Singh J, Khan Y, Seshan SV, Girardi G (2010) A new mouse model to explore therapies for preeclampsia. *PLoS One* 5:13663
- Barker DJ, Thornburg KL, Osmond C, Kajantie E, Eriksson JG (2010) The surface area of the placenta and hypertension in the offspring in later life. *Int J Dev Biol* 54:525–530
- Benediktsson R, Lindsay RS, Noble J, Seckl JR, Edwards CR (1993) Glucocorticoid exposure in utero: new model for adult hypertension. *Lancet* 341:339–341
- Bonnin A, Goeden N, Chen K, Wilson ML, King J, Shih JC, Blakely RD, Deneris ES, Levitt P (2011) A transient placental source of serotonin for the fetal forebrain. *Nature* 472:347–350
- Brown RW, Diaz R, Robson AC, Kotelevtsev YV, Mullins JJ, Kaufman MH, Seckl JR (1996a) The ontogeny of 11 beta-hydroxysteroid dehydrogenase type 2 and mineralocorticoid receptor gene expression reveal intricate control of glucocorticoid action in development. *Endocrinology* 137:794–797
- Brown RW, Chapman KE, Kotelevtsev Y, Yau JL, Lindsay RS, Brett L, Leckie C, Murad P, Lyons V, Mullins JJ, Edwards CR, Seckl JR (1996b) Cloning and production of antisera to human placental 11 beta-hydroxysteroid dehydrogenase type 2. *Biochem J* 313:1007–1017
- Burton PJ, Waddell BJ (1994) 11 β -Hydroxysteroid dehydrogenase in the rat placenta: developmental changes and the effects of altered glucocorticoid exposure. *J Endocrinol* 143:505–513
- Burton PJ, Smith RE, Krozowski ZS, Waddell BJ (1996) Zonal distribution of 11 beta-hydroxysteroid dehydrogenase types 1 and 2 messenger ribonucleic acid expression in the rat placenta and decidua during late pregnancy. *Biol Reprod* 55:1023–1028
- Cottrell EC, Seckl JR (2009) Prenatal stress, glucocorticoids and the programming of adult disease. *Front Behav Neurosci* 3:19
- Cottrell EC, Holmes MC, Livingstone DE, Kenyon CJ, Seckl JR (2012) Reconciling the nutritional and glucocorticoid hypotheses of fetal programming. *FASEB J* 26:1866–1874
- Dave-Sharma S, Wilson RC, Harbison MD, Newfield R, Azar MR, Krozowski ZS, Funder JW, Shackleton CH, Bradlow HL, Wei JQ, Hertecant J, Moran A, Neiberger RE, Balfe JW, Fattah A, Daneman D, Akkurt HI, De Santis C, New MI (1998) Examination of genotype and phenotype relationships in 14 patients with apparent mineralocorticoid excess. *J Clin Endocrinol Metab* 83:2244–2254
- Dodic M, May CN, Wintour EM, Coghlan JP (1998) An early prenatal exposure to excess glucocorticoid leads to hypertensive offspring in sheep. *Clin Sci* 94:149–155
- Dodic M, Peers A, Coghlan JP, May CN, Lumbers E, Yu Z, Wintour EM (1999) Altered cardiovascular haemodynamics and baroreceptor-heart rate reflex in adult sheep after prenatal exposure to dexamethasone. *Clin Sci* 97:103–109
- Dodic M, Hantzis V, Duncan J, Rees S, Koukoulas I, Johnson K, Wintour EM, Moritz K (2002a) Programming effects of short prenatal exposure to cortisol. *FASEB J* 16:1017–1026
- Dodic M, Moritz K, Koukoulas I, Wintour EM (2002b) Programmed hypertension: kidney, brain or both? *Trends Endocrinol Metab* 13:403–408
- Edwards CR, Benediktsson R, Lindsay RS, Seckl JR (1993) Dysfunction of placental glucocorticoid barrier: link between fetal environment and adult hypertension? *Lancet* 341:355–357
- Ericsson A, Hamark B, Jansson N, Johansson BR, Powell TL, Jansson T (2005) Hormonal regulation of glucose and system A amino acid transport in first trimester placental villous fragments. *Am J Physiol Regul Integr Comp Physiol* 288:R656–R662
- Gardner DS, Bell RC, Symonds ME (2007) Fetal mechanisms that lead to later hypertension. *Curr Drug Targets* 8:894–905

- Gatford KL, Wintour EM, De Blasio MJ, Owens JA, Dodic M (2000) Differential timing for programming of glucose homeostasis, sensitivity to insulin and blood pressure by in utero exposure to dexamethasone in sheep. *Clin Sci* 98:553–560
- Guzmán C, Cabrera R, Cárdenas M, Larrea F, Nathanielsz PW, Zambrano E (2006) Protein restriction during fetal and neonatal development in the rat alters reproductive function and accelerates reproductive ageing in female progeny. *J Physiol* 572:97–108
- Hahn T, Barth S, Graf R, Engelmann M, Beslagic D, Reul JM, Holsboer F, Dohr G, Desoye G (1999) Placental glucose transporter expression is regulated by glucocorticoids. *J Clin Endocrinol Metab* 84:1445–1452
- Harris A, Seckl J (2010) Glucocorticoids, prenatal stress and the programming of disease. *Horm Behav* 59:279–289
- Hewitt DP, Mark PJ, Waddell BJ (2006a) Glucocorticoids prevent the normal increase in placental vascular endothelial growth factor expression and placental vascularity during late pregnancy in the rat. *Endocrinology* 147:5568–5574
- Hewitt DP, Mark PJ, Waddell BJ (2006b) Placental expression of peroxisome proliferator-activated receptors in rat pregnancy and the effect of increased glucocorticoid exposure. *Biol Reprod* 74:23–28
- Holmes MC, Abrahamsen CT, French KL, Paterson JM, Mullins JJ, Seckl JR (2006) The mother or the fetus? 11 β -hydroxysteroid dehydrogenase type 2 null mice provide evidence for direct fetal programming of behavior by endogenous glucocorticoids. *J Neurosci* 26:3840–3844
- Jansson N, Greenwood SL, Johansson BR, Powell TL, Jansson T (2003) Leptin stimulates the activity of the system A amino acid transporter in human placental villous fragments. *J Clin Endocrinol Metab* 88:1205–1211
- Jensen EC, Gallaher BW, Breier BH, Harding JE (2002) The effect of a chronic maternal cortisol infusion on the late-gestation fetal sheep. *J Endocrinol* 174:27–36
- Jones HN, Ashworth CJ, Page KR, McArdle HJ (2006) Cortisol stimulates system A amino acid transport and SNAT2 expression in a human placental cell line (BeWo). *Am J Physiol Endocrinol Metab* 291:E596–E603
- Kenouch S, Lomès M, Delahaye F, Eugene E, Bonvalet JP, Farman N (1994) Human skin as target for aldosterone: coexpression of mineralocorticoid receptors and 11 β -hydroxysteroid dehydrogenase. *J Clin Endocrinol Metab* 79:1334–1341
- Kumasawa K, Ikawa M, Kidoya H, Hasuwa H, Saito-Fujita T, Morioka Y, Takakura N, Kimura T, Okabe M (2011) Pravastatin induces placental growth factor (PGF) and ameliorates pre-eclampsia in a mouse model. *Proc Natl Acad Sci U S A* 108:1451–1455
- Langdown ML, Sugden MC (2001) Enhanced placental GLUT1 and GLUT3 expression in dexamethasone-induced fetal growth retardation. *Mol Cell Endocrinol* 185:109–117
- Langley-Evans SC, Philips GJ, Benediktsson R, Gardner DS, Edwards CR, Jackson AA, Seckl JR (1996) Protein intake in pregnancy, placental glucocorticoid metabolism and the programming of hypertension in the rat. *Placenta* 17:169–172
- Lesage J, Blondeau B, Grino M, Bréant B, Dupouy JP (2001) Maternal undernutrition during late gestation induces fetal overexposure to glucocorticoids and intrauterine growth retardation, and disturbs the hypothalamo-pituitary adrenal axis in the newborn rat. *Endocrinology* 142:1692–1702
- Levitt S, Lindsay RS, Holmes MC, Seckl JR (1996) Dexamethasone in the last week of pregnancy attenuates hippocampal glucocorticoid receptor gene expression and elevates blood pressure in the adult offspring in the rat. *Neuroendocrinology* 64:412–418
- Lindsay RS, Lindsay RM, Edwards CR, Seckl JR (1996) Inhibition of 11- β -hydroxysteroid dehydrogenase in pregnant rats and the programming of blood pressure in the offspring. *Hypertension* 27:1200–1204
- Lucassen PJ, Bosch OJ, Jousma E, Krömer SA, Andrew R, Seckl JR, Neumann ID (2009) Prenatal stress reduces postnatal neurogenesis in rats selectively bred for high, but not low, anxiety:

- possible key role of placental 11beta-hydroxysteroid dehydrogenase type 2. *Eur J Neurosci* 29:97–103
- Mairesse J, Lesage J, Breton C, Bréant B, Hahn T, Darnaudéry M, Dickson SL, Seckl J, Blondeau B, Vieau D, Maccari S, Viltart O (2007) Maternal stress alters endocrine function of the foeto-placental unit in rats. *Am J Physiol Endocrinol Metab* 292:E1526–E1533
- Meyer JS (1983) Early adrenalectomy stimulates subsequent growth and development of the rat brain. *Exp Neurol* 82:432–446
- Mune T, Rogerson FM, Nikkilä H, Agarwal AK, White PC (1995) Human hypertension caused by mutations in the kidney isozyme of 11 beta-hydroxysteroid dehydrogenase. *Nat Genet* 10:394–399
- Murphy VE, Zakar T, Smith R, Giles WB, Gibson PG, Clifton VL (2002) Reduced 11beta-hydroxysteroid dehydrogenase type 2 activity is associated with decreased birth weight centile in pregnancies complicated by asthma. *J Clin Endocrinol Metab* 87:1660–1668
- Newnham JP, Jobe AH (2009) Should we be prescribing repeated courses of antenatal corticosteroids? *Semin Fetal Neonatal Med* 14:157–163
- Nyirenda MJ, Lindsay RS, Nyirenda MJ, Lindsay RS, Kenyon CJ, Burchell A, Seckl JR (1998) Glucocorticoid exposure in late gestation permanently programs rat hepatic phosphoenolpyruvate carboxykinase and glucocorticoid receptor expression and causes glucose intolerance in adult offspring. *J Clin Invest* 101:2174–2181
- O'Regan D, Kenyon CJ, Seckl JR, Holmes MC (2004) Glucocorticoid exposure in late gestation in the rat permanently programs gender-specific differences in adult cardiovascular and metabolic physiology. *Am J Physiol Endocrinol Metab* 287:E863–E870
- Pankevich DE, Mueller BR, Brockel B, Bale TL (2009) Prenatal stress programming of offspring feeding behavior and energy balance begins early in pregnancy. *Physiol Behav* 98:94–102
- Roberts D, Dalziel S (2006) Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. *Cochrane Database Syst Rev* 3, CD004454
- Roland BL, Funder JW (1996) Localization of 11beta-hydroxysteroid dehydrogenase type 2 in rat tissues: in situ studies. *Endocrinology* 137:1123–1128
- Roland BL, Krozowski ZS, Funder JW (1995) Glucocorticoid receptor, mineralocorticoid receptors, 11 beta-hydroxysteroid dehydrogenase-1 and -2 expression in rat brain and kidney: in situ studies. *Mol Cell Endocrinol* 111:1–7
- Smith JT, Waddell BJ (2000) Increased fetal glucocorticoid exposure delays puberty onset in postnatal life. *Endocrinology* 141:2422–2428
- Stewart PM, Rogerson FM, Mason JI (1995) Type 2 11 beta-hydroxysteroid dehydrogenase messenger ribonucleic acid and activity in human placenta and fetal membranes: its relationship to birth weight and putative role in fetal adrenal steroidogenesis. *J Clin Endocrinol Metab* 80:885–890
- Stocker C, O'Dowd J, Morton NM, Wargent E, Sennitt MV, Hislop D, Glund S, Seckl JR, Arch JR, Cawthorne MA (2004) Modulation of susceptibility to weight gain and insulin resistance in low birthweight rats by treatment of their mothers with leptin during pregnancy and lactation. *Int J Obes Relat Metab Disord* 28:129–136
- Uldry M, Thorens B (2004) The SLC2 family of facilitated hexose and polyol transporters. *Pflügers Arch* 447:480–489
- Waddell BJ, Benediktsson R, Brown RW, Seckl JR (1998) Tissue-specific messenger ribonucleic acid expression of 11beta-hydroxysteroid dehydrogenase types 1 and 2 and the glucocorticoid receptor within rat placenta suggests exquisite local control of glucocorticoid action. *Endocrinology* 139:1517–1523
- Welberg LA, Seckl JR, Brown RW, Seckl JR (2000) Inhibition of 11beta-hydroxysteroid dehydrogenase, the foeto-placental barrier to maternal glucocorticoids, permanently programs amygdala GR mRNA expression and anxiety-like behaviour in the offspring. *Eur J Neurosci* 12:1047–1054

- Welberg LA, Seckl JR, Holmes MC (2001) Prenatal glucocorticoid programming of brain corticosteroid receptors and corticotrophin-releasing hormone: possible implications for behaviour. *Neuroscience* 104:71–79
- Whorwood CB, Ricketts ML, Stewart PM (1994) Epithelial cell localization of type 2 11 beta-hydroxysteroid dehydrogenase in rat and human colon. *Endocrinology* 135:2533–2541
- Woods LL, Weeks DA (2005) Prenatal programming of adult blood pressure: role of maternal corticosteroids. *Am J Physiol Regul Integr Comp Physiol* 289:R955–R962
- Wyrwoll CS, Mark PJ, Mori TA, Puddey IB, Waddell BJ (2006) Prevention of programmed hyperleptinemia and hypertension by postnatal dietary omega-3 fatty acids. *Endocrinology* 147:599–606
- Wyrwoll CS, Mark PJ, Waddell BJ (2007) Developmental programming of renal glucocorticoid sensitivity and the renin-angiotensin system. *Hypertension* 50:579–584
- Wyrwoll CS, Seckl JR, Holmes MC (2009) Altered placental function of 11beta-hydroxysteroid dehydrogenase 2 knockout mice. *Endocrinology* 150:1287–1293

Hormones, Intrauterine Health and Programming

Seckl, J.R.; Christen, Y. (Eds.)

2014, XIV, 189 p. 10 illus., 9 illus. in color., Hardcover

ISBN: 978-3-319-02590-2